KR102393125B9 - A Composition for Preventing or Treating Protein Conformational Disorders with Activity of Autophagy Induction Comprising Kaempferide as an Active Ingredient - Google Patents

A Composition for Preventing or Treating Protein Conformational Disorders with Activity of Autophagy Induction Comprising Kaempferide as an Active Ingredient

Info

Publication number
KR102393125B9
KR102393125B9 KR1020190101275A KR20190101275A KR102393125B9 KR 102393125 B9 KR102393125 B9 KR 102393125B9 KR 1020190101275 A KR1020190101275 A KR 1020190101275A KR 20190101275 A KR20190101275 A KR 20190101275A KR 102393125 B9 KR102393125 B9 KR 102393125B9
Authority
KR
South Korea
Prior art keywords
kaempferide
activity
preventing
composition
active ingredient
Prior art date
Application number
KR1020190101275A
Other languages
Korean (ko)
Other versions
KR20210021828A (en
KR102393125B1 (en
Inventor
권호정
김다솔
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Priority to KR1020190101275A priority Critical patent/KR102393125B1/en
Priority to PCT/KR2020/011015 priority patent/WO2021034094A1/en
Publication of KR20210021828A publication Critical patent/KR20210021828A/en
Application granted granted Critical
Publication of KR102393125B1 publication Critical patent/KR102393125B1/en
Publication of KR102393125B9 publication Critical patent/KR102393125B9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020190101275A 2019-08-19 2019-08-19 A Composition for Preventing or Treating Protein Conformational Disorders with Activity of Autophagy Induction Comprising Kaempferide as an Active Ingredient KR102393125B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020190101275A KR102393125B1 (en) 2019-08-19 2019-08-19 A Composition for Preventing or Treating Protein Conformational Disorders with Activity of Autophagy Induction Comprising Kaempferide as an Active Ingredient
PCT/KR2020/011015 WO2021034094A1 (en) 2019-08-19 2020-08-19 Composition comprising kaempferide as active ingredient for prevention or treatment of protein conformational disorder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020190101275A KR102393125B1 (en) 2019-08-19 2019-08-19 A Composition for Preventing or Treating Protein Conformational Disorders with Activity of Autophagy Induction Comprising Kaempferide as an Active Ingredient

Publications (3)

Publication Number Publication Date
KR20210021828A KR20210021828A (en) 2021-03-02
KR102393125B1 KR102393125B1 (en) 2022-05-02
KR102393125B9 true KR102393125B9 (en) 2023-08-04

Family

ID=74660695

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020190101275A KR102393125B1 (en) 2019-08-19 2019-08-19 A Composition for Preventing or Treating Protein Conformational Disorders with Activity of Autophagy Induction Comprising Kaempferide as an Active Ingredient

Country Status (2)

Country Link
KR (1) KR102393125B1 (en)
WO (1) WO2021034094A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240074253A (en) 2022-11-21 2024-05-28 경북대학교 산학협력단 Composition for inhibiting skin pigmentation through autophagy activity containing procyanidin A2 and quercetin, as active ingredients

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101076199B1 (en) 2009-01-28 2011-10-21 현대제철 주식회사 Method for Manufacturing Thick Steel Plate
US9745279B2 (en) * 2011-12-27 2017-08-29 Tokiwa Phytochemical Co., Ltd. Sirtuin activator

Also Published As

Publication number Publication date
WO2021034094A1 (en) 2021-02-25
KR20210021828A (en) 2021-03-02
KR102393125B1 (en) 2022-05-02

Similar Documents

Publication Publication Date Title
ZA202001887B (en) Composition for preventing or treating tnf-related diseases, containing novel derivative as active ingredient, and method for inhibiting tnf activity by using same
IL268850A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
IL278178A (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
SG11202011018PA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
SG11202011010YA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
IL287032A (en) Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
EP3906241A4 (en) Inhibitors of cgas activity as therapeutic agents
GB201907616D0 (en) Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
IL286636A (en) Compositions and methods for the treatment of kras associated diseases or disorders
IL287280A (en) Compounds and methods for the treatment of ocular disorders
MY201535A (en) Therapeutic compounds
IL285452A (en) New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
MX2022000845A (en) Inhibitor compounds.
EP2578590A4 (en) Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same
EP3906229A4 (en) Inhibitors of cgas activity as therapeutic agents
WO2014110198A3 (en) Therapeutic indications of kinase inhibitors
IL270927B (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
KR102393125B9 (en) A Composition for Preventing or Treating Protein Conformational Disorders with Activity of Autophagy Induction Comprising Kaempferide as an Active Ingredient
EP3936124A4 (en) Pharmaceutical composition for preventing or treating neurological diseases
EP3970711A4 (en) Composition for preventing or treating cardio-cerebrovascular diseases comprising autophagy activator as active ingredient
IL288234A (en) Compounds for the treatment of neuromuscular disorders
EP3795170C0 (en) Pharmaceutical composition comprising ccn5 as active ingredient for preventing or treating retinal diseases
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
KR102091567B9 (en) Pharmaceutical composition for prevention or treatment of brain injury comprising the osteopontin protein fragment as an active ingredient

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
G170 Re-publication after modification of scope of protection [patent]